Aprea Therapeutics (APRE) Cash from Operations (2018 - 2026)
Aprea Therapeutics (APRE) posted quarterly Cash from Operations of 2756726.0 for Q1 2026, up 24.08% year-over-year from 2221706.64 in Q1 2025, and up 6.91% quarter-over-quarter from 2961292.0 in Q4 2025.
Aprea Therapeutics (APRE) Cash from Operations (2018 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Cash from Operations for 9 consecutive years, with 2756726.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 24.08% year-over-year to 2756726.0; the TTM figure through Mar 2026 stood at 12020002.0 (up 9.3% YoY), while the FY2025 annual figure was 12894439.0, up 4.89% from the prior year.
- Cash from Operations climbed to 2756726.0 in Q1 2026 per APRE's latest filing, from 2961292.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 2241965.0 in Q3 2023 and bottomed at 8902613.0 in Q2 2022.
- Historically, Cash from Operations has averaged 3905683.94 across 5 years, with a median of 3510904.0 in 2024.
- Annual changes were most pronounced in 2023 — Cash from Operations soared 65.99% — and 2024, when it sank 32.12%.
- Aprea Therapeutics' Cash from Operations stood at 4020512.0 in 2022, then advanced by 6.99% to 3739658.0 in 2023, then grew by 6.12% to 3510904.0 in 2024, then rose by 15.65% to 2961292.0 in 2025, then grew by 6.91% to 2756726.0 in 2026.
- Business Quant data shows APRE's Cash from Operations at 2756726.0 in Q1 2026, 2961292.0 in Q4 2025, and 3171230.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Aprea Therapeutics | 34.25 Mn | 34.25 Mn | - | -3.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.28 Mn |
| Jun 30, 2026 | -3.28 Mn |
| Mar 31, 2026 | -2.76 Mn |
| Mar 31, 2026 | -2.76 Mn |
| Dec 31, 2025 | -2.96 Mn |
| Dec 31, 2025 | -2.96 Mn |
| Sep 30, 2025 | -3.17 Mn |
| Sep 30, 2025 | -3.17 Mn |
| Jun 30, 2025 | -3.13 Mn |
| Jun 30, 2025 | -3.13 Mn |
| Mar 31, 2025 | -3.63 Mn |
| Mar 31, 2025 | -3.63 Mn |
| Dec 31, 2024 | -3.51 Mn |
| Dec 31, 2024 | -3.51 Mn |
| Sep 30, 2024 | -2.47 Mn |
| Sep 30, 2024 | -2.47 Mn |
| Jun 30, 2024 | -3.64 Mn |
| Jun 30, 2024 | -3.64 Mn |
| Mar 31, 2024 | -3.94 Mn |
| Mar 31, 2024 | -3.94 Mn |